Search
People
Timo LassmannFeilman Fellow; Program Head, Precision Health and Team Lead, Computational Biology
News & Events
Pioneering paediatric oncologist receives top cancer research awardAssociate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.
News & Events
Continuing the cancer fightWork by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.
Research
Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumoursThe class 1A aldehyde dehydrogenase (ALDH1A) subfamily of genes encode enzymes that function at the apex of the retinoic acid (RA) signalling pathway.
Research
Vehicle refuelling, use of domestic wood heaters and the risk of childhood brain tumours: Results from an Australian case-control studyThe aetiology of childhood brain tumours (CBT) is largely unknown.
Research
Participation in paediatric cancer studies: Timing and approach to recruitmentIn this sub-study, we aimed to investigate factors that may have influenced study participation and completeness of survey completion.
Research
Chemotherapy increases amenability of surgical resection in congenital glioblastomaBrain tumors presenting in infancy, especially during the first 6 months of life.
Research
Exposure to professional pest control treatments and the risk of childhood acute lymphoblastic leukemiaPrevious studies suggest that exposure to pesticides increases the risk of childhood acute lymphoblastic leukemia
Research
Pediatric meningioma: Current approaches and future directionWith improvement in leukemia therapy, central nervous system (CNS) tumors are the leading cause of cancer mortality in children and the most expensive...
Research
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthAnti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory.